Oak Hill Bio In The Press

Making Headlines in Advancing Rare Disease Therapies.

FEATURED IN WSJ PRO

Oak Hill Bio Squares Off Against Big Rivals to Find Angelman Treatment

Read Full Article [Reprint]

Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome

Oak Hill Bio Spotlights Publication Detailing Discovery and Initial Development of Rugonersen in Nucleic Acids Research

September 9, 2025

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome